Healthcare innovation

Sygen promises to improve lives, sector through…

Business_2669727f-640x360.jpg

Sygen promises to improve lives, sector through…

Sygen Pharmaceuticals, one of Nigeria’s healthcare manufacturing companies, has promised to improve and enrich lives of Nigerians, through innovation in science, in the communities where they operate.

Speaking at the formal brand launch, held in Onikan, Lagos, Chief Executive Officer, Sygen, Charles Ogunwuyi, said Sygen manufactures and markets a wide range of products, including anti-malaria, antihypertensive and anti-diabetics, among other products.

He explained that Sygen aims to spotlight its plans to transform the pharmaceutical sector in Nigeria and value chain in the West African region through research and innovation.

Ogunwuyi noted that Sygen Pharmaceuticals formally introduces corporate brand in Nigeria, with the goal of promoting communal well being for all Nigerians. Established in March 2019, with the plans to drive innovation in the pharmaceutical industry, including promoting overall communal well-being for all Nigerians.

He said the pharmaceutical company is led by a management team with extensive multinational and international work experience, and determined to develop and create access to high-quality medicines that yield successful outcomes and improve patients’ quality of life in the communities where it operates.

General Manager, Sales for Lagos and Southwest, Sygen, Kachi Akwari, said the innovative pharmaceutical company subsequently acquired the assets of Nigerian German Chemicals (NGC) Plc., to expand its pharmaceutical product portfolio. Akwari said Sygen Pharmaceuticals product portfolio currently includes drugs in the following categories: anti-diabetics, antipyretics, multivitamin, analgesic, anti-rheumatic, antifungal, antispasmodic, among others.

He said: “Sygen Pharmaceutical was established to grant access to high-quality medicines that yield successful outcomes and improve the quality of life of patients in our community, through our innovative approach to enhancing healthcare outcomes. At Sygen, we look beyond the functionality of providing medicines and seek to drive the total well-being of communities in a way that is vital to society.”

He said there is a need in the pharmaceutical industry to shift the focus from humans as patients to people living in thriving communities, as Sygen Pharmaceutical puts this in practice with the goal of promoting communal well-being and thriving communities.

Akwari noted that Sygen is building a reputation with its product quality and supply continuity. “The company continues to build a wide-ranging portfolio of products across brands and plans to rapidly expand its product line.

“With its formal brand launch, Sygen Pharmaceutical will redirect the focus on medicine as a function of ill health to providing a better life for communities altogether,” Akwari said.

He explained that since inception, Sygen Pharmaceuticals has established itself as a reputable organisation within the pharmaceutical and healthcare industry and has gained the trust and respect of key stakeholders.

“In addition to the portfolio of branded products acquired from NGC, Sygen will continue to grow its product portfolio across various therapeutic areas. The organisation is driven by the quest to make a difference in the lives of people and communities. As a result, Sygen Pharma strives for continuous improvement and innovation geared toward expanding access to good-quality medicines in communities.”

Akwari stated that Sygen acquired NGC because it is a company that had operated in Nigeria for almost 60 years and has a range of legacy brands with strong residual equity in its product portfolio. He said Sygen Pharmaceuticals Limited is an ISO 9001:2015 Certified Company by Société Générale de Surveillance (SGS), and benchmarks its materials and products specification with the Nigeria statutory, Legal and Regulatory Guidelines/Regulations, United States Pharmacopeia (USP) and British Pharmacopeia (BP) standards.

Source

Leave your thought here

Your email address will not be published. Required fields are marked *